Abstracts tagged "Vasculitis"

Abstract Number: 0763 • ACR Convergence 2025
Diagnostic Utility of Temporal Artery Biopsy in Giant Cell Arteritis: A Single Center Experience
wendy Perdomo, Sean Welch and Timothy Wilson, Thomas Jefferson University, Philadelphia, PA
Background/Purpose: Giant cell arteritis (GCA) is predominantly large vessel vasculitis that has a specific prediliction for vasculature of the head, eyes and jaw and if…
Abstract Number: 0737 • ACR Convergence 2025
Effectiveness and Safety of Janus Kinase Inhibitors in Giant Cell Arteritis. Real-World Clinical Practice Study and Literature Review
Ana Serrano-Combarro¹, Fernando Lopez Gutierrez², Javier Loricera³, toluwalase Tofade⁴, Diana Prieto-Peña⁵, Susana Romero-Yuste⁶, Eugenio de Miguel⁷, Anne Riveros frutos⁸, DALIFER FREITES⁹, Ivan Ferraz Amaro¹⁰, Santos Castañeda¹¹, Eztizen Labrador-Sanchez¹², Olga Maiz¹³, Elena Becerra-Fernández¹⁴, Javier Narváez¹⁵, Eva Galíndez Agirregoikoa¹⁶, Ismael González¹⁷, Ana Urruticoechea-Arana¹⁸, Angel Ramos Calvo¹⁹, Patricia Moya Albarado²⁰, Sebastian H Unizony²¹ and Ricardo Blanco²², ¹Division of Rheumatology, Hospital Universitario Marques de Valdecilla, IDIVAL, Inmunopathology group, Santander, Santander, Spain, ²Hospital Universitario Marqués de Valdecilla, Immunopathology Group -IDIVAL, Reumatología, Santander, Santander, Spain, ³Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, ⁴Massachussetts General Hospital, Boston, MA, ⁵Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Santander, Spain, ⁶University Hospital Complex of Pontevedra, Pontevedra, Spain, ⁷Hospital Universitario La Paz, Madrid, Spain, ⁸Hospital Germans Trias i Pujol, Barcelona, Spain, ⁹Rheumatology Service, San Carlos Clinical Hospital, Madrid, Madrid, Spain, ¹⁰Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ¹¹Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Madrid, Spain, ¹²Hospital Universitario San Pedro, Laguardia, Spain, ¹³Hospital Universitario de Donostia, San Sebastián, Pais Vasco, Spain, ¹⁴Hospital Universitario de Elda, Alicante, Comunidad Valenciana, Spain, ¹⁵Hospital Universitario de Bellvitge, Barcelona, Spain, ¹⁶BASURTO UNIVERSITY HOSPITAL, BILBAO, Spain, ¹⁷Complejo Asistencial Universitario de León, León, Castilla y Leon, Spain, ¹⁸Hospital Son Espases, Palma de Mallorca, Islas Baleares, Spain, ¹⁹Complejo Hospitalario de Soria, Soria, Castilla y Leon, Spain, ²⁰Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ²¹Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²²Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain
Background/Purpose: Patients with giant cell arteritis (GCA) can relapse despite glucocorticoids, methotrexate and tocilizumab treatment. The JAK/STAT signalling pathway is involved in the pathogenesis of…
Abstract Number: PP03 • ACR Convergence 2025
My Journey of Risk, Loss, and Hope: The Role of Multidisciplinary Collaboration in Managing Pregnancy with Takayasu Arteritis
Tugce Turten Kaymaz
Background/Purpose: At the age of 26, the same month I got married, I was diagnosed with Takayasu Arteritis following severe chest and back pain. Hypertension…
Abstract Number: 2513 • ACR Convergence 2025
Beyond Clinical trials in Eosinophilic Granulomatosis with Polyangiitis: A Systematic Review of effectiveness and safety data derived from real-world evidence of Mepolizumab 300 mg
Iñigo Rúa-Figueroa¹, Beatriz Velasco² and Maria Cid³, ¹Hospital de Gran Canaria Doctor Negrin, Las Palmas GC, Spain, ²GSK, Madrid, Spain, ³Department of Autoimmune Diseases (member of European Reference Network RITA), Hospital Clinic, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is characterized by systemic necrotizing vasculitis affecting small and medium-sized vessels, and defined by the presence of eosinophilia, extravascular…
Abstract Number: 1626 • ACR Convergence 2025
A Delphi Exercise Informing the Development of Criteria to Measure Response to Treatment in Giant Cell Arteritis
Medha Soowamber¹, Milena Bond², Catalina Sanchez Alvarez³, Carol Langford⁴, Sibel Aydin⁵, FRANK BUTTGEREIT⁶, Dario Camellino⁷, Maria Cid⁸, Peter Grayson⁹, Bernhard Hellmich¹⁰, Tanaz Kermani¹¹, Nader Khalidi¹², Sarah Mackie¹³, Alfred Mahr¹⁴, Eric L Matteson³, Mehrdad Maz¹⁵, Peter Merkel¹⁶, Paul Monach¹⁷, Lorna Neill¹⁸, Cristina Ponte¹⁹, Carlo Salvarani²⁰, Wolfgang Schmidt²¹, Peter Villiger²², Kenneth Warrington²³, Christian Dejaco²⁴, Sofia Ramiro²⁵ and Zahi Touma²⁶, ¹Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ²South Tyrol Health Trust and Teaching Hospital of the Paracelsus Medical University, Brunico, Italy, ³Mayo Clinic College of Medicine and Science, Rochester, MN, ⁴Cleveland Clinic, Moreland Hills, OH, ⁵Department of Medicine, University of Ottawa, The Ottawa Hospital Research Institute, Ottawa, ON, Canada, ⁶Charité University Medicine Berlin, Berlin, Berlin, Germany, ⁷"La Colletta" hospital, Azienda Sanitaria Locale ³ Genovese, Arenzano, Italy, ⁸Department of Autoimmune Diseases (member of European Reference Network RITA), Hospital Clinic, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain, ⁹National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Chevy Chase, MD, ¹⁰Department of Internal Medicine, Rheumatology, Pulmonology, Nephrology and Diabetology, Medius Kliniken Kirchheim/Teck, University Tübingen, Tübingen, Germany, Kirchheim-Teck, Germany, ¹¹David Geffen School of Medicine, University of California, Los Angeles, CA, ¹²Department of Medicine, McMaster University and St. Joseph’s Healthcare, Hamilton, Canada, ¹³University of Leeds, Leeds, United Kingdom, ¹⁴Klinik für Rheumatologie, Kantonspital St Gallen, St Gallen, Switzerland, ¹⁵The University of Kansas Medical Center, Kansas City, KS, ¹⁶University of Pennsylvania, Philadelphia, PA, ¹⁷VA Boston Healthcare System, Boston, MA, ¹⁸Patient Charity Polymyalgia Rheumatica and Giant Cell Arteritis Scotland, Nethy Bridge, United Kingdom, ¹⁹Unidade Local de Saúde de Santa Maria, Lisbon, Portugal, ²⁰Unit of Rheumatology, Azienda USL - IRCCS di Reggio Emilia, and University of Modena and Reggio Emilia, Reggio Emilia, Italy, ²¹Immanuel Krankenhaus Berlin, Medical Centre for Rheumatology Berlin-Buch; Waldfriede Hospital, Rheumatology, Berlin, Germany, ²²Medical Center Monbijou, Rheumatology and Clinical Immunology, Bern, Switzerland, ²³Mayo Clinic, ROCHESTER, MN, ²⁴Medical University of Graz, Graz, Austria, ²⁵Leiden University Medical Center, Bunde, Netherlands, ²⁶University of Toronto, Toronto, ON, Canada
Background/Purpose: The therapeutic landscape of giant cell arteritis (GCA) is growing rapidly but there are currently no internationally standardized criteria for assessing response to treatment…
Abstract Number: 1592 • ACR Convergence 2025
Mepolizumab to Benralizumab Switch in Eosinophilic Granulomatosis with Polyangiitis (EGPA)
Adrien Cottu¹, Irene Mattioli², Xavier Puéchal³, Loic Guillevin⁴, Mathieu Groh⁵, Camille Taillé⁶, Maxime Samson⁷, Pascal Cathébras⁸, Halil Yildiz⁹, Grégory Pugnet¹⁰, Stéphane Jouneau¹¹, Marie-Charlotte Besse¹², François Lifermann¹³, Jean-Philippe Martellosio¹⁴, Laurent Guilleminault¹⁵, Colas Tcherakian¹⁶, Yann Nguyen¹⁷, Claire Demoreuil¹⁸, Philippe Guilpain¹⁹, Giacomo Emmi²⁰ and Benjamin Terrier²¹, ¹Internal medicine departement, Cochin Hospital, Paris, France, ²Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, ³Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hospital Cochin, and Université Paris Cité, Paris ( ⁷⁵⁰¹⁴ ), Ile-de-France, France, ⁴Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hospital Cochin, Paris, France, ⁵Hôpital Foch, Suresnes, France, ⁶Bichat hospital, APHP, Paris, France, ⁷CHU Dijon Bourgogne, Dijon, France, ⁸Internal medicine department, CHU St-Etienne, Saint-Etienne, France, ⁹Internal medicine department, Saint-Luc, Saint-Luc, France, ¹⁰CHU Toulouse Rangueil Service de Medecine Interne et Immunologie Clinique, Toulouse, France, ¹¹Respiratory Medicine, Université de Rennes ¹, CHU Pontchaillou, Rennes, France, ¹²Tours University Hospital, ³⁷⁰⁰⁰ tours, Ile-de-France, France, ¹³Internal Medicine, CH de Dax, Dax, France, ¹⁴Internal medicine department, CHU Poitiers, Poitiers, France, ¹⁵CHU Toulouse, Toulouse University, Toulouse, France, ¹⁶Pneumology department, Foch, Suresnes, France, ¹⁷Department of Internal Medicine, Beaujon Hospital, AP-HP Nord, Université Paris Cité, Clichy, France, Clichy, France, ¹⁸Internal medicine department, Brest CHU, Brest, France, ¹⁹Internal medicine department, CHU Montpellier, Montpellier, France, ²⁰Department of Medical, Surgery and Health Sciences, University of Trieste, Italy and Clinical Medicine and Rheumatology Unit, Cattinara University Hospital, Trieste, Italy, Trieste, Italy, ²¹Cochin Hospital, Paris, France
Background/Purpose: Glucocorticoid (GC)-dependent asthma and ENT exacerbations may persist in more than half of patients with eosinophilic granulomatosis with polyangiitis (EGPA). Mepolizumab and benralizumab, monoclonal…
Abstract Number: 0760 • ACR Convergence 2025
The Efficacy Of Targeted Therapies In Giant Cell Arteritis: A Systematic Review and Meta-Analysis
Sema Kaymaz-Tahra¹, Cansu Arslantürk Güneysu², Sinem Nihal Esatoglu³, Güllü Sandal Uzun⁴, Burak Ince⁵, Mete Kara⁶ and Gulen Hatemi³, ¹Bahcesehir University Faculty of Medicine Department of Internal Medicine Division of Rheumatology, Istanbul, Turkey, ²Sakarya Training and Research Hospital, Division of Rheumatology, Sakarya, Turkey, ³Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ⁴Hacettepe University, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey, ⁵Istanbul University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul, ⁶Izmir City Hospital, Division of Rheumatology, Izmir
Background/Purpose: To assess the sustained remission rates of the targeted therapies in 52th week in patients with giant cell arteritis (GCA).Methods: We performed a systematic…
Abstract Number: 0732 • ACR Convergence 2025
Blocking GM-CSF receptor alpha with mavrilimumab reduces production of growth factors involved in vascular remodeling in an ex-vivo model of temporal artery culture from patients with giant-cell arteritis (GCA)
marc Corbera-bellalta¹, Roser Alba-Rovira¹, Nina Visocnik¹, Farah Kamberovic¹, Ferran Araujo-Ayala¹, Georgina Espigol-Frigolé¹, Patricia Perez-Galán¹, Ken Bondensgaard², John Paolini³ and Maria Cid⁴, ¹Hospital Clínic. University of Barcelona. IDIBAPS., Barcelona, Spain, ²Kiniksa Pharmaceuticals, Lexington, ³Kiniksa Pharmaceuticals, LEXINGTON, MA, ⁴Department of Autoimmune Diseases (member of European Reference Network RITA), Hospital Clinic, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
Background/Purpose: Background: Giant-cell arteritis(GCA) is a chronic inflammatory disease targeting large and medium-sized arteries. Inflammation-induced vascular remodeling leads to vascular occlusion, with ischemic complications. Myofibroblasts…
Abstract Number: 2701 • ACR Convergence 2025
Ophthalmic Manifestations of Relapsing Polychondritis
Akash Gupta¹, Rennie Rhee², Kaitlin Quinn³, Naomi Amudala², Nirali Bhatt⁴, Carol McAlear², Marcela ferrada⁵, Peter Grayson⁶, Peter Merkel² and Shubhasree Banerjee², ¹Hospital of University of Pennsylvania, Philadelphia, PA, ²University of Pennsylvania, Philadelphia, PA, ³National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ⁴Scheie Eye Institute, University of Pennsylvania, Philadelphia, PA, ⁵University of Maryland, Bethesda, MD, ⁶National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Chevy Chase, MD
Background/Purpose: The prevalence of ocular involvement (OI) in patients with relapsing polychondritis (RP) has not been well defined. This study aimed to describe ocular manifestations,…
Abstract Number: 2510 • ACR Convergence 2025
Impact of ANCA specificity on risk of severe infection occurrence in ANCA-associated vasculitis.
Clara Rouane¹, Jon Idoate¹, Morgane Mourguet¹, Thomas Villeneuve¹, Grégoire Prevot¹, Laurent Guilleminault², Stan Faguer¹, Antoine Huart¹, David Ribes¹, Dominique Chauveau¹, Martin Michaud¹, Laurent Sailler¹, Sébastien De Almeida Chaves¹, Emmanuelle Mouchon¹, Guillaume De Bonnecaze¹, Margaux Lafaurie¹, Guillaume Moulis¹ and Grégory Pugnet³, ¹CHU Toulouse, Toulouse, France, ²CHU Toulouse, Toulouse University, Toulouse, France, ³CHU Toulouse Rangueil Service de Medecine Interne et Immunologie Clinique, Toulouse, France
Background/Purpose: ANCA specificity has shown an association with patients’ genetic profile, cytokine profile, certain clinical presentations, serologic response to treatment, and risk of recurrence.Severe infections…
Abstract Number: 1624 • ACR Convergence 2025
Disease activity status in Takayasu’s arteritis influences the angiogenic potential of patient-derived endothelial cells
Luciana Yamamoto de Almeida¹, Kaitlin Quinn², James Simone², Lily Dai², Benjamin Turturice², Urvashi Kaundal², Chloe Palmer², Karyssa Stonick³, davide Randazzo⁴, Carmelo Carmona-Rivera⁵ and Peter Grayson⁶, ¹National Institutes of Health, Bethesda, MD, ²National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ³National Insitute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, ⁴Light Imaging Section, Office of Science and Technology, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, Bethesda, ⁵Systemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, Bethesda, MD, ⁶National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Chevy Chase, MD
Background/Purpose: Takayasu's arteritis (TAK) is a rare, systemic, chronic large vessel vasculitis of unknown etiology primarily affecting the aorta and its branches. Arterial damage, with…
Abstract Number: 1147 • ACR Convergence 2025
Renal Manifestations in VEXAS Syndrome: A Systematic Review of Clinical Features, Pathology, and Outcomes
Akhila Arya Perumangote Vasudevan¹, Vishnu Mulavini², Rasiya Hashim³, Madhumitha Rondla⁴ and Dileep C Unnikrishnan⁵, ¹Yale University/Bridgeport Hospital, Stratford, CT, ²Calicut Medical College, Stratford, ³Franciscan Health Olympia & Chicago Heights, [email protected], IL, ⁴Texas tech university health sciences center, El paso, El Paso, TX, ⁵Bridgeport Hospital, Stratford, CT
Background/Purpose: VEXAS syndrome is a recently described, adult-onset autoinflammatory disease caused by somatic mutations in the UBA1 gene, typically affecting hematopoietic stem cells. Renal involvement…
Abstract Number: 0759 • ACR Convergence 2025
Distinct differences between giant cell arteritis diagnosed by fluorodeoxyglucose (FDG) positron emission tomography (PET) versus temporal artery biopsy-a comparative cohort study
Sehreen Mumtaz¹, Lerone Clark², Archit Srivastava², Hannah Langenfeld³, Andrew C. Hanson³, Cynthia Crowson⁴, Andy Abril², Nouran Eshak⁵, Megan Sullivan⁶, Matthew Koster³ and Kenneth Warrington³, ¹Mayo Clinic Florida, Jacksonville, FL, ²Mayo Clinic, Florida, Jacksonville, FL, ³Mayo Clinic, Rochester, MN, ⁴Mayo Clinic, Stewartvillle, MN, ⁵Mayo Clinic, Arizona, Scottsdale, AZ, ⁶Mayo Clinic Arizona, Scottsdale, AZ
Background/Purpose: Giant cell arteritis (GCA) is clinically heterogenous, and the presenting manifestations may influence diagnostic testing. The aim of this study was to evaluate the…
Abstract Number: 0730 • ACR Convergence 2025
Levels of Disease Activity and Their Relationship With Health-Related Quality of Life In ANCA-Associated Vasculitis Patients: Data from the Almenara Vasculitis Cohort
Victor Pimentel-Quiroz¹, Alvaro Oyarce-Calderón², Allison Figueroa-Sánchez³, Leonor León-Yaurimucha³, Rocío Gamboa-Cárdenas⁴, Zoila Rodríguez-Bellido⁵, Risto Perich-Campos⁶, Graciela Alarcón⁷ and Manuel Ugarte-Gil⁸, ¹Universidad Científica del Sur, San Isidro, Peru, ²Hospital Nacional Guillermo Almenara Irigoyen, San Miguel, Lima, Peru, ³Universidad Científica del Sur, Lima, Peru, ⁴Universidad Científica del Sur, Lima, Peru, ⁵Hospital Nacional Guillermo Almenara Irigoyen; Universidad Nacional Mayor de San Marcos, Lima, Peru, ⁶Hospital Nacional Guillermo Almenara Irigoyen; Universidad Nacional Mayor de San Marcos, La Molina, Peru, ⁷The University of Alabama at Birmingham, Oakland, CA, ⁸Universidad Cientifica del Sur, Lima, Peru
Background/Purpose: It is known that health-related quality of life (HRQoL) in patients with ANCA-associated vasculitis (AAV) is impaired. Categories of disease activity levels have been…
Abstract Number: 2700 • ACR Convergence 2025
Neutrophil Transcriptomics and Maturation Pathways in VEXAS Syndrome
Chloe Palmer¹, Gustaf Wigerblad², Tom Hill³, Benjamin Turturice¹, Urvashi Kaundal¹, Paul Schaughency³, Bhavisha Patel⁴, Emma Groarke⁵, Neal Young⁵, Stefania Dell'orso¹ and Peter Grayson⁶, ¹National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ²National Institutes of Health, Stockholm, Sweden, ³NIAID, NIH, Bethesda, MD, ⁴National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH), Beltsville, MD, ⁵National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH), Bethesda, MD, ⁶National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Chevy Chase, MD
Background/Purpose: VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is a severe adult-onset inflammatory disease caused by somatic mutations of the ubiquitin-like modifier activating enzyme…

« Previous Page
1
…
3
4
5
6
7
…
41
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].